Effect of Familial Longevity on Frailty and Sarcopenia: A Case-Control Study.

Familial longevity confers advantages in terms of health, functionality, and longevity. We sought to assess potential differences in frailty and sarcopenia in older adults according to a parental history of extraordinary longevity. A total of 176 community-dwelling subjects aged 65-80 years were recruited in this observational case-control study, pair-matched 1:1 for gender, age, and place of birth and residence: 88 centenarians' offspring (case group) and 88 non-centenarians' offspring (control group). The main variables were frailty and sarcopenia based on Fried's phenotype and the European Working Group on Sarcopenia in Older People (EWGSOP) definitions, respectively. Sociodemographics, comorbidities, clinical and functional variables, the presence of geriatric syndromes, and laboratory parameters were also collected. Related sample tests were applied, and conditional logistic regression was performed. Cases had a higher percentage of robust patients (31.8% vs. 15.9%), lower percentages of frailty (9.1% vs. 21.6%) and pre-frailty (59.1% vs. 62.5%) (p = 0.001), and lower levels of IL-6 (p = 0.044) than controls. The robust adjusted OR for cases was 3.00 (95% CI = 1.06-8.47, p = 0.038). No significant differences in muscle mass were found. Familial longevity was also associated with less obesity, insomnia, pain, and polypharmacy and a higher education level and total and low-density lipoprotein cholesterol. The results suggest an inherited genetic component in the frailty phenotype, while the sarcopenia association with familial longevity remains challenging.

Oxidative stress and exceptional human longevity: Systematic review.

OBJECTIVE: Oxidative stress (OS) has been previously linked to the aging process, as have some diseases and geriatric syndromes as frailty and sarcopenia. The aim of the present study was to perform a systematic review on oxidative stress activity and extreme longevity in humans. METHODS: We conducted a systematic literature review following the PRISMA guidelines. Observational studies assessing OS-biomarkers and/or antioxidants in long-lived individuals (97 years old or over) comparing them to those of one or more age groups, (at least one of which from comprising elderly subjects) were considered for inclusion. A narrative synthesis was planned. Quality of selected studies was assessed using the Newcastle-Ottawa quality assessment scale (NOS). RESULTS: After screening and eligibility phases, 12 articles were finally selected, with 646 long-lived participants and 1052 controls, 447 adults (20-60 years old) and 605 elderly individuals (over 60 years old). The average score on NOS scale of studies was 4,8 out of 9. Centenarians showed significantly less (p<0,05) oxidative damage to lipids in different samples, lower levels of oxidized proteins in plasma and lower superoxide anion levels in neutrophils than elderly groups. Centenarian presented significantly lower superoxide dismutase and higher glutathione reductase activities, higher levels of vitamins A and E, lower of coenzyme Q10, and lower susceptibility to lipid peroxidation than elderly controls. CONCLUSION: Based on studies of medium-low quality, available evidence suggests that long-lived individuals display less oxidative damage, particularly lower plasma lipid peroxidation biomarkers, than controls. More studies with better experimental designs are needed.

Influence of hospital adverse events and previous diagnoses on hospital care cost of patients with hip fracture.

Previous diagnoses of patients with hip fracture influence the hospitalization cost of these patients, either directly or by increasing the risk of in-hospital adverse events associated with increased costs. PURPOSE: To investigate how previous diagnoses influence the occurrence of in-hospital adverse events and how both factors impact on hospital costs. METHODS: This is a retrospective analysis of the hospital Minimum Basic Data Set. Patients aged 70 years or older admitted for hip fracture (HF) at a single University Hospital between January 2012 and December 2016. Both, previous diagnoses and adverse events, were defined according to the International Classification of Diseases (ICD-9/ICD-10). The anticipated cost of each admission was calculated based on diagnosis-related groups and using the "all patients refined" method (APR-DRG). The occurrence of adverse events during hospital stay was assessed by excluding all diagnoses present on admission. RESULTS: The record included 1571 patients with a mean (SD) age of 84 years. The most frequent previous diagnoses were diabetes (n = 432, 27.5%) and dementia (n = 251, 16.0%), and the most frequent adverse events were delirium (n = 238, 15.1%) and anemia (n = 188, 12.0%). The mean (SD) total acute care costs per patient were €8752.1 (1864.4). The presence of heart failure, COPD, and kidney disease at admission significantly increased the hospitalization cost. In-hospital adverse events of delirium, cardiac events, anemia, urinary tract infection, and digestive events significantly increased costs. The multivariate analyses identified kidney disease as a previous diagnosis significantly contributing to explain an increase in hospitalization costs, and delirium, cardiac disease, anemia, urinary infection, respiratory event, and respiratory infection as in-hospital adverse events significantly contributing to an increase of hospitalization costs. CONCLUSIONS: Although few baseline comorbidities have a direct impact on hospitalization costs, most previous diagnoses increase the risk of in-hospital adverse events, which ultimately influence the hospitalization cost.

Spanish list of potentially inappropriate drugs in the elderly (ES-PIA project).

PURPOSE: In the last decades, different criteria have been developed for detecting inappropriate prescription in older patients. In Spain, translations and adaptations of international lists are available but it would be necessary a national list which could cope with the peculiarities of our health system, existing pharmaceutical market, and prescription habits. We propose in this project the creation of a Spanish potentially inappropriate drugs list which could be applicable in our clinical scenario. METHODS: We use a Delphi method involving 25 experts from different backgrounds (Clinical Pharmacology, Geriatrics, Rational Use of Drugs and Pharmacy, Primary Care and Pharmacoepidemiology, and Pharmacovigilance) that were asked to participate in two-round questionnaires. For analysis, current recommendations of Worth and Pigni were applied, and every statement was classified into one of three groups: strong, moderate, or low agreement. Statements with strong agreement were accepted to be part of the inadequate prescription list. Moderate agreement statements were selected to enter the second questionnaire, and statements with low agreement were further analyzed to determine if it was due to heterogeneity or due to dispersion in the answers. RESULTS: The first questionnaire consisted of 160 proposed sentences, of which 106 reached a high agreement, 32 a moderate agreement, and 22 a low agreement. All sentences proposed in the second questionnaire reached a strong agreement. The total accepted sentences were 138. CONCLUSIONS: We offer a list of inadequate prescription in older patients adapted to the Spanish pharmacopeia and according to the prescription habits in our environment.

Estimate of the Costs Caused by Adverse Effects in Hospitalised Patients Due to Hip Fracture: Design of the Study and Preliminary Results.

INTRODUCTION: Hip fracture is a health problem that presents high morbidity and mortality, negatively influencing the patient's quality of life and generating high costs. Structured analysis of quality indicators can facilitate decision-making, cost minimization, and improvement of the quality of care. METHODS: We studied 1571 patients aged 70 years and over with the diagnosis of hip fracture at Hospital Universitario de la Ribera in the period between 1 January 2012 and 31 December 2016. Demographic, clinical, functional, and quality indicator variables were studied. An indirect analysis of the costs associated with adverse events arising during hospital admission was made. A tool based on the "Minimum Basic Data Set (CMBD)" was designed to monitor the influence of patient risk factors on the incidence of adverse effects (AE) and their associated costs. RESULTS: The average age of the patients analysed was 84.15 years (SD 6.28), with a length of stay of 8.01 days (SD 3.32), a mean preoperative stay of 43.04 h (SD 30.81), and a mortality rate of 4.2%. Likewise, the percentage of patients with AE was 41.44%, and 11.01% of patients changed their cost as a consequence of these AEs suffered during hospital admission. The average cost of patients was €8752 (SD: 1,864) and the average cost increase in patients with adverse events was €2321 (SD: 3,164). CONCLUSIONS: Through the analysis of the main clinical characteristics and the indirect estimation of the complexity of the patients, a simple calculation of the average cost of the attention and its adverse events can be designed in patients who are admitted due to hip fracture. Additionally, this tool can fit the welfare quality indicators by severity and cost.

El estrés oxidativo como predictor de longevidad; estudio de casos y controles / Oxidative stress and longevity; a case-control study

Introducción. La longevidad humana es un fenómeno complejo en el que influyen factores genéticos y ambientales. El estrés oxidativo (EO) puede jugar un papel importante en este proceso. El envejecimiento exitoso podría relacionarse con la habilidad del organismo para hacer frente al EO. Nuestro objetivo es comparar los niveles en plasma de malondialdehído (MDA) y proteínas oxidadas (PO) entre sujetos mayores de 97 años y con edad entre 70 y 80 años, para comprender mejor los efectos del estrés oxidativo en la longevidad humana. Material y métodos. Estudio de casos y controles de base poblacional. Se consideraron casos todas aquellas personas nacidas y residentes en la comarca de la Ribera (Valencia), con edad superior a 97 años y que aceptaron participar en el mismo. Los controles son sujetos de la misma base poblacional, elegidos al azar, y con edad entre 70 y 80 años. Se realiza un análisis descriptivo de variables sociodemográficas, clínicas y funcionales; se calcula la razón de odds (OR) de ser centenario en función del cuartil de los niveles de PO y MDA; y la significación estadística de la tendencia mediante el test Mantel-Haenszel. Resultados. Fueron incluidos 28 casos y 31 controles. La situación funcional, así como el porcentaje de individuos robustos, fue menor en el grupo de casos que en los controles. Los niveles de MDA fueron menores en los casos (1,44 ± 0,45 vs. 1,84 ± 0,59, p = 0,005), al igual que los niveles de PO (64,29 ± 15,73 vs. 76,52 ± 13,44, p = 0,002). Al comparar a los sujetos con niveles de MDA y PO en el cuartil inferior respecto al superior, la OR de ser centenario es de 3,8 para el MDA y de 5,7 para las PO, con una p = 0,029 y p = 0,044, respectivamente, en la significación de la tendencia. Conclusiones. En los sujetos de nuestro estudio los niveles plasmáticos de MDA y PO son menores en centenarios que en ancianos más jóvenes, y se observa que a menor grado de EO mayor es la probabilidad de ser centenario (AU)

Introduction. Human longevity is a complex issue influenced by genetic and environmental factors. Oxidative stress (OE) could play an important role in this process. Succesful aging could be related with the organism ability facing OE. In the present study we compared malondialdehyde (MDA) and oxidized proteins (OP) plasma levels, in elderly people older than 97 years and 70-80 years old, to better understand the effects of OE on human longevity. Material and methods. Population-based case control study. We considered as cases patients who were born and live on la Ribera county in Valencia (Spain) older than 97 years old and who accepted to participate in the study. Controls were from the same poblational base, chosen randomly, and 70-80 years old. We made a descriptive analysis of sociodemographic, clinic and functional variables; an odds ratio (OR) estimation of being centenarian by OP and MDA quartiles; and a tendency analysis by Mantel-Haenszel test. Results. Twenty eight cases and 31 controls were included. Functional state and robust percentage were worse in cases. MDA (1,44 ± 0,45 vs 1,84 ± 0,59, p = 0,005), and OP (64,29 ± 15,73 vs. 76,52 ± 13,44, p = 0,002) levels, were significantly lower in cases. The OR of being centenarian in lower/higher quartile were 3,8 for MDA and 5,7 for OP, with a Mantel-Haenszel signification of 0,029 and 0,044 respectively. Conclusions. In our study OE level were lower in centenarians than in younger elderly, and the lower the OE grade, the higher were the likelihood of being centenarian (AU)

Severity of cognitive impairment as a prognostic factor for mortality and functional recovery of geriatric patients with hip fracture.

AIM: To identify how the severity of dementia influences functional recovery and mortality in elderly patients hospitalized for hip fracture. METHODS: An observational retrospective study of 1258 patients aged older than 69 years and diagnosed with hip fracture who received care within an orthogeriatrics unit from 2004 to 2008 was carried out. During a 12-month follow-up period, functional recovery and mortality outcomes were measured. RESULTS: Dementia was present in 383 (28.1%) patients: it was mild in 183 (48%), moderate in 102 (26.5%) and severe in 98 (25.5%). Compared with patients with preserved cognitive status, patients with dementia had the following statistically significant differences (means [standard deviation] or percentage): older age (preserved, 82.29 years [6.5 years]; mild, 83.63 years [6.1 years]; moderate, 83.47 years [5.9 years]; severe, 84.46 years [6.1 years]; P < 0.001); lower Barthel Index (89.7 [21.6], 72.7 [24.6], 58.9 [28.6], 38.0 [28.1]; P < 0.001); delirium (11.7%, 25.6%, 37.6%, 44.7%; P < 0.001); less ambulation at 6 months postdischarge (83.9%, 72.8%, 56.9%, 41.7%; P < 0.001); and higher mortality at discharge (4%, 5.7%, 8.2%, 10.6%; P < 0.001) and 12 months after discharge (21.2%, 32.3%, 46.3%, 53.5%; P < 0.001). Patients with severe dementia had lower probability of functional recovery at discharge (OR 0.272, 95% CI 0.140-0.526, P < 0.001) and 6 months after discharge (OR 0.439, 95% CI 0.197-0.979, P = 0.04), as well as a greater probability of dying (HR 1.640, 95% CI 1.020-2.635, P = 0.04). CONCLUSIONS: We observed higher 12-month mortality and less functional recovery with increasing severity of dementia.

[Oxidative stress and longevity; a case-control study]. / El estrés oxidativo como predictor de longevidad; estudio de casos y controles.

INTRODUCTION: Human longevity is a complex issue influenced by genetic and environmental factors. Oxidative stress (OE) could play an important role in this process. Succesful aging could be related with the organism ability facing OE. In the present study we compared malondialdehyde (MDA) and oxidized proteins (OP) plasma levels, in elderly people older than 97 years and 70-80 years old, to better understand the effects of OE on human longevity. MATERIAL AND METHODS: Population-based case control study. We considered as cases patients who were born and live on la Ribera county in Valencia (Spain) older than 97 years old and who accepted to participate in the study. Controls were from the same poblational base, chosen randomly, and 70-80 years old. We made a descriptive analysis of sociodemographic, clinic and functional variables; an odds ratio (OR) estimation of being centenarian by OP and MDA quartiles; and a tendency analysis by Mantel-Haenszel test. RESULTS: Twenty eight cases and 31 controls were included. Functional state and robust percentage were worse in cases. MDA (1,44±0,45 vs 1,84±0,59, p=0,005), and OP (64,29±15,73 vs. 76,52±13,44, p=0,002) levels, were significantly lower in cases. The OR of being centenarian in lower/higher quartile were 3,8 for MDA and 5,7 for OP, with a Mantel-Haenszel signification of 0,029 and 0,044 respectively. CONCLUSIONS: In our study OE level were lower in centenarians than in younger elderly, and the lower the OE grade, the higher were the likelihood of being centenarian.

Early interdisciplinary hospital intervention for elderly patients with hip fractures : functional outcome and mortality.

OBJECTIVES: Hip fractures are associated with high levels of co-morbidity and mortality. Orthogeriatric units have been shown to be effective with respect to functional recovery and mortality reduction. The aim of this study is to document the natural history of early multidisciplinary intervention in elderly patients with hip fractures and to establish the prognostic factors of mortality and walking ability after discharge. METHODS: This observational, retrospective study was performed in an orthogeriatric care unit on patients aged >70 years with a diagnosis of hip fracture between 2004 and 2008. This study included 1363 patients with a mean age of 82.7 + 6.4 years. RESULTS: On admission to the unit, the average Barthel score of these patients was 77.2 + 27.8 points, and the average Charlson index score was 2.14 + 2.05. The mean length of stay was 8.9 + 4.26 days, and the readmission rate was 2.3%. The in-hospital mortality rate was 4.7%, and the mortality rates at one, six, and 12 months after discharge were 8.7%, 16.9%, and 25.9%, respectively. The Cox proportional hazards model estimated that male sex, Barthel scale, heart failure, and cognitive impairment were associated with an increased risk of death. With regard to functionality, 63.7% of the patients were able to walk at the time of discharge, whereas 77.4% and 80.1% were able to walk at one month and six months post-discharge, respectively. The factors associated with a worse functional recovery included cognitive impairment, performance status, age, stroke, Charlson score, and delirium during the hospital stay. CONCLUSIONS: Early multidisciplinary intervention appears to be effective for the management of hip fracture. Age, male sex, baseline function, cognitive impairment and previous comorbidities are associated with a higher mortality rate and worse functional recovery.

Adecuación de la utilización de benzodiazepinas en ancianos desde la oficina de farmacia. Un estudio de colaboración médico-farmacéutico / Suitability of the use of benzodiazepines prescribed by the pharmacist in the elderly. A doctor-pharmacist collaboration study

Objetivos: Mejorar el uso de benzodiazepinas (BZD) en ancianos desde una colaboración farmacéutico-médica. Diseño: Se realizó un estudio controlado simple ciego durante un año en farmacias con la finalidad de conseguir que las BZD sean eficaces, seguras y se utilicen el tiempo necesario. Emplazamiento: Once farmacias comunitarias de la Comunidad Valenciana. Participantes: Pacientes mayores de 65años tratados con BZD que acudieron a las farmacias participantes durante el periodo del estudio. Intervenciones: Entrevistas y seguimiento farmacoterapéutico durante un año. Medidas principales: Detección de duplicidades, reacciones adversas al medicamento, interaccciones farmacológicas y medida de la efectividad del tratamiento. Resultados: Se estudiaron 314 pacientes, distribuidos de forma aleatoria al grupo control o intervención, que utilizaban 346 BZD. El 67% utilizaban BZD durante más de 1 año. Solo el 5% de los pacientes con insomnio conocía que la duración del tratamiento debía ser inferior al mes. El 20% utilizaban BZD de vida larga, 76% de vida media y el 4% de vida corta. Se detectaron 132 interacciones farmacológicas y 278 RAM: 32% pérdida de memoria, 21% somnolencia, 12% incoordinación motora, 8,3% mareo y confusión, 8,3% desorientación y 10% otras. Se realizaron 426 intervenciones farmacéuticas, 30 aceptadas por el médico, y se resolvieron 78 al finalizar el año. El 30% de los casos del grupo intervención fueron satisfactorios, y solo 11% del control. Conclusiones: Las benzodiazepinas se utilizan en los pacientes ancianos de la Comunidad Valenciana con mayor frecuencia y por periodos más prolongados de lo recomendado por la Agencia Española del Medicamento(AU)

Aims: To improve the use of benzodiazepines (BZD) in the elderly by a pharmacist-physician collaboration, and to insure that BZD are effective, safe, and used as long as necessary. Design: A single blind controlled study was conducted on 11 pharmacies in the Community of Valencia. Setting: Eleven pharmacies in the Community of Valencia. Participants: Patients older than 65years treated with BZD attending the participating pharmacies. Interventions: Interviews and pharmaceutical care for a year. Main measurement: detection of duplications, adverse drug reactions, drug interactions and measuring the effectiveness of the treatment. Results: We studied 314 patients, randomised to control or intervention and who used 346 BZD. The majority (67%) of patients used BZD for more than 1 year. Only 5% patients with anxiety knew the duration of treatment should be one month. Long-acting BZD were used by 20% of the patients, 76% used medium-acting (39% lorazepam and 37% other BZD) and 4% short-acting BZD. A total of 132 drug interactions were detected and 278 adverse drug reactions: 32% memory loss, 21% drowsiness, 12% lack of coordination, 8.3% dizziness and confusion, 8,3% disorientation and 10% others. A total of 426 pharmacist interventions were performed, 30 accepted by the doctor and 78 were resolved at the end of the year of study. Eleven per cent of cases were considered satisfactory in the control group and 30% in the intervention group. Conclusion: The use of benzodiazepines in the Community of Valencia exceeds the recommendations of the Spanish Medicines Agency(AU)

[Suitability of the use of benzodiazepines prescribed by the pharmacist in the elderly. A doctor-pharmacist collaboration study]. / Adecuación de la utilización de benzodiazepinas en ancianos desde la oficina de farmacia. Un estudio de colaboración médico-farmacéutico.

AIMS: To improve the use of benzodiazepines (BZD) in the elderly by a pharmacist-physician collaboration, and to insure that BZD are effective, safe, and used as long as necessary. DESIGN: A single blind controlled study was conducted on 11 pharmacies in the Community of Valencia. SETTING: Eleven pharmacies in the Community of Valencia. PARTICIPANTS: Patients older than 65 years treated with BZD attending the participating pharmacies. INTERVENTIONS: Interviews and pharmaceutical care for a year. MAIN MEASUREMENT: detection of duplications, adverse drug reactions, drug interactions and measuring the effectiveness of the treatment. RESULTS: We studied 314 patients, randomised to control or intervention and who used 346 BZD. The majority (67%) of patients used BZD for more than 1 year. Only 5% patients with anxiety knew the duration of treatment should be one month. Long-acting BZD were used by 20% of the patients, 76% used medium-acting (39% lorazepam and 37% other BZD) and 4% short-acting BZD. A total of 132 drug interactions were detected and 278 adverse drug reactions: 32% memory loss, 21% drowsiness, 12% lack of coordination, 8.3% dizziness and confusion, 8,3% disorientation and 10% others. A total of 426 pharmacist interventions were performed, 30 accepted by the doctor and 78 were resolved at the end of the year of study. Eleven per cent of cases were considered satisfactory in the control group and 30% in the intervention group. CONCLUSION: The use of benzodiazepines in the Community of Valencia exceeds the recommendations of the Spanish Medicines Agency.

Early interdisciplinary hospital intervention for elderly patients with hip fractures : functional outcome and mortality

OBJECTIVES: Hip fractures are associated with high levels of co-morbidity and mortality. Orthogeriatric units have been shown to be effective with respect to functional recovery and mortality reduction. The aim of this study is to document the natural history of early multidisciplinary intervention in elderly patients with hip fractures and to establish the prognostic factors of mortality and walking ability after discharge. METHODS: This observational, retrospective study was performed in an orthogeriatric care unit on patients aged >70 years with a diagnosis of hip fracture between 2004 and 2008. This study included 1363 patients with a mean age of 82.7 + 6.4 years. RESULTS: On admission to the unit, the average Barthel score of these patients was 77.2 + 27.8 points, and the average Charlson index score was 2.14 + 2.05. The mean length of stay was 8.9 + 4.26 days, and the readmission rate was 2.3%. The in-hospital mortality rate was 4.7%, and the mortality rates at one, six, and 12 months after discharge were 8.7%, 16.9%, and 25.9%, respectively. The Cox proportional hazards model estimated that male sex, Barthel scale, heart failure, and cognitive impairment were associated with an increased risk of death. With regard to functionality, 63.7% of the patients were able to walk at the time of discharge, whereas 77.4% and 80.1% were able to walk at one month and six months post-discharge, respectively. The factors associated with a worse functional recovery included cognitive impairment, performance status, age, stroke, Charlson score, and delirium during the hospital stay. CONCLUSIONS: Early multidisciplinary intervention appears to be effective for the management of hip fracture. Age, male sex, baseline function, cognitive impairment and previous comorbidities are associated with a higher mortality rate and worse functional recovery.